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Abstract
The sporadic nature in over 90% of Alzheimer’s disease (AD) cases, the differential susceptibility
and course of illness, and latent onset of the disease suggest involvement of an environmental
component in the etiology of late onset AD (LOAD). Recent reports from our lab have
demonstrated that molecular alterations favor abundant tau phosphorylation and immunoreactivity
in the frontal cortex of aged primates with infantile lead (Pb) exposure (Bihaqi and Zawia, 2013).
Here we report that developmental Pb exposure results in elevation of protein and mRNA levels of
tau in aged mice. Western blot analysis revealed aberrant site-specific tau hyperphosphorylation
accompanied by elevated cyclin dependent kinase 5 (CDK5) levels in aged mice with prior Pb
exposure. Mice with developmental Pb exposure also displayed altered protein ratio of p35/p25
with more Serine/Threonine phosphatase activity at old age. These changes favored increase in tau
phosphorylation, thus providing evidence that neurodegenerative diseases may be in part due to
environmental influences that occur during development.
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1. Introduction
The neurodegenerative disorder Alzheimer’s disease (AD) is the most prominent form of
dementia among elderly in Western countries (Hebert et al., 2003). At the pathological level,
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AD is characterized by excessive accumulation of two major proteinaceous aggregates,
senile plaques composed of aggregated amyloid beta (Aβ), which is derived from the β-
amyloid precursor protein (APP), and neurofibrillary tangles enriched with
hyperphosphorylated tau. These pathological hallmarks are responsible for synaptic loss in
the brain resulting in dementia (Selkoe, 1991, Tanzi and Bertram, 2008).
Although the familial early onset (<65years) form of AD (EOAD) has been linked to
mutations in the amyloid precursor protein (APP), presenilin 1 (PSEN 1), presenilin 2
(PSEN2), late onset AD (LOAD) that represents the majority of AD cases (~95%) is
sporadic in nature and has no genetic association (Liddell et al., 2001). Moreover, the
pathological manifestation of AD which occur in old age, may have been set in motion prior
to such a stage, and possibly during early stages of brain development (Zawia and Basha,
2005). The developing brain is specifically vulnerable to the neurotoxic effects of lead (Pb),
a widely recognized neurotoxin (Mushak et al., 1989). While there are no conclusive
evidence available which can pin point a precise correlation between Pb exposure and AD,
however studies in the ageing individuals have shown a possible association between Pb
exposure and cognitive decline in human subjects (Nordberg et al., 2000, Weisskopf et al.,
2007). This was corroborated by recent findings from a 2-year lifespan study in rodents
which demonstrated that rodents with developmental exposure to Pb showed cognitive
deficit as aged adults, which is consistent with changes in amyloid biomarkers of AD
(Bihaqi et al., 2013).
Evidence of the association between exposure to Pb and cognitive decline in humans is
present from several longitudinal and cross-sectional studies in the elderly. Cognitive
decline is an intermediate stage towards the development of AD. The Normative Aging
Study (NAS) is a prospective longitudinal study that the Veterans Administration started in
1963 to monitor the effect of aging on different health conditions (Peters et al., 2010) with
sub-groups of population investigated for a link between past non-occupational Pb exposure
and cognitive decline. Participants in NAS were examined by several investigators, with
different cognitive tests, sample size and time periods, who reported that higher levels of Pb
in blood and/or bone were accompanied by poor cognitive performance in different
cognitive tests including Wechsler Adult Intelligence Scale-Revised (WAIS-R), Consortium
to Establish a Registry for AD (CERAD) and Mini-Mental state examination (MMSE)
(Payton et al., 1998, Wright et al., 2003, Weisskopf et al., 2004, Weisskopf et al., 2007). In a
sub-group of the Nurses’ Health Study (NHS), a longitudinal study established in 1976 to
monitor women health, (Weuve et al., 2009) reported that in 587 women exposed to Pb,
higher levels of Pb in tibia bone were associated with poor test scores on MMSE. Moreover,
in a cross-sectional study that involved 530 women of age between 65–87 years, blood Pb
concentrations of ≥8μg/dL significantly resulted in a poor performance in several cognitive
tests including MMSE, incidental memory test and digit symbol test (Muldoon et al., 1996).
Despite the negative effects of Pb exposure on cognitive functions in elderly population as
suggested by those longitudinal and cross-sectional studies, the need for studies that link the
exposure to Pb, especially in infantile or childhood stages, and incidence of AD arises.
For over a decade our work had focused on Pb exposure and amyloidosis. Recently we have
turned our attention to the co-existent tau pathology. Furthermore, neurofibrillary
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degeneration devoid of amyloidosis has been visualized in several tauopathies like Guam
parkinsonism dementia complex, dementia pugilistica, corticobasal degeneration, Pick's
disease and FTDP-17 tau (fronto-temporal dementia with parkinsonism linked with
chromosome 17 and tau mutations) and progressive supra nuclear palsy (Iqbal et al., 2010).
Furthermore, dementia in humans is best correlated with the presence of neurofibrillary
pathology than β-amyloidosis.
Current published studies by us on primate brains exposed to Pb as infants have shown that
developmental exposure to Pb induces a latent overexpression of tau accompanied by site
specific hyperphosphorylation of tau as well as increased tau immunoreactivity in the frontal
cortex (Bihaqi and Zawia, 2013). In this manuscript we examine the cerebral cortices from a
lifespan study carried out in a cohort of mice with developmental and adult Pb exposure
scenarios in order to profile stage- and exposure specific changes in the tau mRNA and
protein, its phosphorylated forms, as well as other critical intermediates involved in its
regulation.
2. Materials and methods
2.1. Animal exposure
Mice of C57BL/6 strain were bred in-house at the University of Rhode Island. Postnatal day
1 (PND 1) was designated as 24 hours after birth. Male pups from different dams were
pooled and placed randomly to different dams (10 mice/dam). The mice were divided into
four groups. The control group received regular tap water. The second group (PbE, the early
Pb exposure group) was exposed to 0.2% Pb acetate from PND 1 to PND 20 through
drinking water of the dam. The third group (PbA, the adult lead exposure group) was
exposed to Pb daily for 3 months starting at 7 months of age. The fourth group (PbEA, the
early and adult Pb exposure group [re-exposure as adults]) was exposed to Pb
developmentally (PND 1 to PND 20) and during adulthood (7–9 months of age). The mice
were sacrificed and their brains dissected out at PNDs: 20, 180, 270, 540, and 700 and their
frontal cortices were stored at −80°C until use (Fig 1). (Figure 1)
2.2. Sample preparation and Western blotting
Brain cortical tissues were lysed or homogenized in RIPA lysis buffer (lysis buffer (150 mM
NaCl, 25 mM Tris-HCl at pH 8.0, 1% NP-40, 10 mM NaF, 1mM Na3VO4) containing 1%
protease inhibitors cocktail (Sigma-Aldrich, MO), The samples were sonicated and vortexed
for 5min prior to centrifugation at 10,000 x g for 20 min at 4°C to pellet the cell debris, the
supernatant obtained was used for Western blot analysis. Protein concentration was
determined by using a BCA kit (Pierce Biotechnology Inc. Rockford, IL). Immunoblotting
for total tau, phosphorylated tau and associated proteins was determined following over
night exposure at 4°C to the following antibodies diluted at 1:1000: mouse anti-Tau 46, anti-
phospho-Tau [rabbit anti pThr-212 (Sigma Aldrich, MO), rabbit anti p-Thr-181, mouse anti
pSer-396 (Cell Signaling technology, MA), rabbit anti p-Ser 235 (Abcam, MA)], rabbit anti-
CDK5, and rabbit anti p35/25 (C64B10) (Cell Signaling technology, MA). On the following
day, membranes were washed and exposed for 1 h to goat anti mouse/goat anti rabbit
IRDye® 680LT infrared dye (LI-COR Biotechnology, NE), diluted at 1:10,000. The images
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were developed using Odyssey infrared imaging system (Model- 9120, LI-COR
Biotechnology, NE). As a control for equal protein loading, membranes were stripped and
reprobed for 2 h with mouse glyceraldehydes 3 phosphate dehydrogenase (GAPDH)
antibody diluted at1:5000 (Sigma-Aldrich, MO) at room temperature followed by washing
and re-exposure to goat anti mouse IRDye® 680LT infrared dye. After transferring to a
polyvinylidene fluoride (PVDF) membrane, the gel was stained with Bio-safe Coomassie
blue stain (Bio-Rad, Hercules, CA) to assess the loading of the samples. The protein
expressions of the various protein analyzed in the present study where normalized against
GAPDH, which is normally used as reference gene product.
2.3. Total RNA isolation, synthesis of complementary DNA, and real-time polymerase chain
reaction
Total RNA from control and exposed brain tissue was extracted according to TRIzol method
(Invitrogen, CA). First strand complementary DNA (cDNA) was synthesized from 1.5 μg of
total RNA using the iScript cDNA kit (Bio-Rad, CA). cDNA was then amplified using real-
time PCR. The SYBR Green qRT-PCR assays were performed in 25 μl reactions in
replicates using 1.5 μl of cDNA template, 1×SYBR Green master mix, 0.4 μM forward and
reverse primers, and deionized water. The following primer pairs were used: tau forward
primer 5′-GTG GCC AGG TGG AAG TAA AA-3’, tau reverse primer 5′-TGG AAG ACA
CAT TGC TGA GG-3′; CDK5 forward primer: 5′-TGG TGA AGC AGG CAT CTG AG-3′,
CDK5 reverser primer 5′-CCA TTG CAG CTG TCG AAA TA-3′; GAPDH forward primer
5′-TGG TGA AGC AGG CAT CTG AG-3′, GAPDH reverse primer 5′-TGC TGT TGA
AGT CGC AGG AG-3′. Amplification was undertaken on an ABI PRISM 7500 machine
(Applied Biosystems, Foster City, CA, USA) with sequence detection software version 1.3,
and expression was reported relative to GAPDH mRNA with the 2−Δ ΔCt method.
2.4. Ser/Thr phosphatase assay
Evaluation of serine/threonine phosphatase (Ser/Thr) activity in mice cortices samples was
done using the Ser/Thr phosphatase assay kit 1 (Millipore, CA). Protein amount of 10 μg
and 200 mM peptide (KRpTIRR) substrate were used per well to determine enzyme activity
after a 15 min reaction. The enzyme reaction was terminated with 100 μl Malachite Green
solution and a subsequent 15 min was allowed for color development. Absorbance was
measured at 650 nm with a plate reader (SpectraMax M5; Molecular Devices, Sunnyvale,
CA). Enzyme activity was calculated from the amount of released phosphate in pmol
phosphate/min/mg based on a phosphate standard curve.
2.5. Statistical analysis
Western blot bands were quantified by using the LI-COR Odyssey infrared image system.
All measurements were made in triplicate and all values are presented as mean standard
error of the mean. The significance of the difference among means of the experimental
groups was obtained with one-way analysis of variance, the Tukey-Kramer multiple-
comparison post-hoc test, and the student Newman-Keuls comparison post-hoc test, using
Graph pad Prism 3.0 computer software (La Jolla, CA, USA). The level of significance was
set at P<0.05.
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3.1. Latent effect of Pb on total tau protein and mRNA
The protein expression of total tau was examined by Western blot analysis at different time
points within the lifespan of the mice of various experimental groups. Our results revealed
that compared to controls, normalized tau levels in PbE (developmental exposure) and PbEA
(developmental and adult exposure) groups were slightly elevated during early life (PND
20) and remained constant during adulthood. However, a significant (P<0.01) increase in
the tau protein expression was observed in late life (PND 700) as compared to controls (Fig.
2A&B). In comparison to the aged matched controls, aged mice exposed to Pb as adults
(PbA) showed no significant change in tau protein expression (Fig. 2A&B). Our results also
revealed that PbE and PbEA groups showed a significant latent upregulation in the mRNA
levels of tau at PND 270 (P<0.05),PND 540 ( P<0.001), and PND 700
(P<0.001)respectively (Fig. 2C).
3.2. Phosphorylation of tau
For tau specific phosphorylation, four different antibodies namely threonine 212 (Thr-212),
threonine 181(Thr-181), serine 396 (Ser-396), and serine 235 (Ser-235) were used in
Western blots of the cerebral cortex. Western blot analysis normalized against GAPDH
revealed that PbE and PbEA depicted a significant (P<0.05) increase in the levels of
(Thr-181), (Ser-396), and (Ser-235) at PND 700 as compared to aged matched control (Fig.
3 and Fig. 4). Similar increases in the levels of (Thr-212) was also observed in these mice in
old age but were not statistically significant. No significant change in tau specific
phosphorylation was observed in the PbA group compared to their respective aged matched
controls (Fig. 3 and Fig. 4).
3.3. Effect of Pb exposure on CDK5 and p35/p25 protein levels
The elevated phosphorylation observed in aged mice at various tau residues in PbE and
PbEA due to developmental Pb exposure can be associated with increases in kinases and
other activators. Our results revealed that PbE and PbEA groups displayed a significant
increase in the normalized protein levels of the kinase CDK5 at PND 540 (P<0.05) and
PND 700 (P<0.05) (Fig. 5A&B). Furthermore a similar upregulation in the mRNA levels of
cdk5 in PbE and PbEA groups at PND 180 (P<0.05), PND 270 (P<0.05), PND 540
(P<0.05, P<0.01) and PND 700 (P<0.05, P<0.01) was seen.No change in the mRNA levels
of cdk5 was observed in PbA group as compared to controls (Fig. 5C).
The alteration in cdk5 protein levels was also accompanied by a subsequent decrease in the
levels of p35, a specific neuronal activator of cdk5 at PND 700 (Fig. 6A&B). Moreover, a
significant (P<0.01) increase in the normalized protein levels of p25 (truncated form of p35)
was observed at PND 500 (P<0.01) and PND 700 (P<0.01) in PbE and PbEA groups as
compared to age matched control (Fig. 6A&C).
3.4. Activity of serine/ threonine phosphatase
We investigated the activity of serine/ threonine phosphatase in the cerebral cortex of the
mice of all experimental groups, control as well as mice with Pb exposure at different time
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points within the life span. Our results revealed that PbE and PbEA groups showed a
significant (P<0.05) increase in the serine/ threonine phosphatase activity at PND 540 and
PND 700 as compared to age-matched control. PbA group registered an insignificant
increase in the activity of serine/ threonine phosphatase at old age compared to age-matched
control (Fig. 7).
4.0. Discussion
The involvement of environmental factors in disease etiology is becoming increasing
noticeable. Heavy metal such as Pb have been found to pose an environmental concern and
its consistent presence in the environment is a health risk to human populations (Tong et al.,
2000). Studies have also revealed that cognitive deficit caused by childhood Pb exposure
can prevail in adulthood (Mazumdar et al., 2011). Although Pb exposure has been projected
as a risk factor for the health of adults and young ones, studies carried out in our lab on
rodents and primates have provided strong proof indicating that early life exposure is
associated with latent effects contributing to the neurodegenerative process (Bihaqi et al.,
2011, Bihaqi et al., 2013).
The protein tau is one of the microtubule associated proteins, mainly found in neuronal
axons and is thought to have a role in the stabilization of neuronal microtubules; which in
turn supports intracellular transport (Mandelkow and Mandelkow, 1994). The failure of
regular tau function can be catastrophic, and its consequences can promote
neurodegenerative disease (Gendron and Petrucelli, 2009). In vitro investigations have also
indicated that overexpression of tau leads to altered cell shapes and reduced cell growth
which eventually results in a dramatically redistribution of various organelles transported by
microtubule-dependent motor proteins (Ebneth et al., 1998). Recent studies from our lab
have shown that aged primates with developmental Pb exposure showed a significant
increase in the tau protein and mRNA levels. Tau immunoreactivity was also found to be
increased in these primates compared to control (Bihaqi and Zawia, 2013).Consistent with
our primate findings mice exposed to Pb during the developmental phases showed a drastic
increase in the protein and mRNA levels of tau in their old age.
A primary hallmark of tau in AD is the presence of abnormal phosphorylation at serine and
threonine sites compared to normal adult brain tau, which leads to the formation of
neurofibrillary tangles (NFT) (Lee et al., 2004). Aberrant phosphorylation of tau is
responsible for compromising microtubule stability and function, resulting in a loss or
decline in axonal or dendritic transport in disease (Alonso et al., 1996, Salehi et al., 2003).
Seminal work carried out by Iqbal and co-workers observed impaired microtubule assembly
in AD brain extracts was associated with tau hyperphosphorylation (Iqbal et al., 2010).
Recently studies carried out in our lab showed that 23 year-old primates with developmental
exposure to Pb exhibit an increase in phosphorylation at Thr 181, Thr 212, Ser 396, and Ser
235 (Bihaqi and Zawia, 2013). Similar to our previous findings, our present study revealed
that mice with developmental exposure to Pb displayed increased phosphorylation at serine
and threonine sites.
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Phosphorylated sites of tau found in AD brains are proline-directed (Thr-Pro or Ser-Pro),
suggestive of the involvement of kinases such as cdk5 (Imahori and Uchida, 1997). Studies
have shown cdk5 to co-localize with the NFT-containing neurons in the AD brains
(Takahashi et al., 2000). Interactions of cdk5 with proteins p35 or p39, which are present in
abundance in post mitotic neurons, are pivotal for its activation (Tomizawa et al., 2002). The
transformation of p35 to p25 is guided by calpain which delocalizes and deregulates cdk5,
and over-activation of cdk5 due to p25 has been associated with NFT (Cruz et al., 2003).
Primate studies undertaken in our lab have shown increased cdk5 and p25 levels in aged
primates with developmental exposure to Pb (Bihaqi and Zawia, 2013). Consistent with
these results, we observed an upregulation of protein and mRNA levels of cdk5
accompanied by a decrease in p35 and a subsequent increase in p25 in aged mice with
developmental Pb exposure. These observation indicate that the post-translational regulators
of tau may be also candidate for epigenetic reprogramming which can have an impact on the
tau gene expression, which can result not only in an increase of total tau, but also in
enzymes which are involved in its phosphorylation.
Protein Phosphatase like protein phosphatase 1 (PP1), protein phosphatase 2A (PP2A) and
protein phosphatase 2B (PP2B) are the major phosphatases found in the brain (Liu et al.,
2007), with PP2A constituting around 90% of the total protein phosphatase activity (Gong et
al., 1995). Several lines of evidence have shown over expression of PP1, PP2A and PP2B in
human primary neuron culture are associated with Pb exposure, and these imbalance in the
activity of phosphatases have also been associated with cognitive dysfunction (Rahman et
al., 2011). Seminal studies by Bihaqi et al have also shown that aged primates with infantile
exposure to Pb display an increase in the activity of the Ser/Thr activity thus resulting in
variable changes in the activity of cdk5. In agreement with our earlier findings, the present
data also reveal that mice with developmental Pb exposure pose a latent over-activation of
Ser/Thr protein phosphatase activity at old age. We have also previously explained that the
increase in protein phosphatase activity was to compensate for the increasing activity of
kinase levels. However the process seemingly advocates more kinase activity leading to
over-burden of tau phosphorylation.
In conclusion our study suggests that early life exposure to the environmental toxicant Pb
up-regulates tau protein and mRNA, as well as tau phosphorylation levels late in life. These
changes were also related to an imbalance in the kinase-phosphatase equilibrium leading to
over abundance of phosphorylated tau.
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Developmental exposure to lead (Pb) alters expression of the tau gene later in life.
Prior Pb exposure increased cdk5 levels and enhanced tau phosphorylation.
Increased Ser/ Thr Phosphatase activity due to developmental exposure to Pb.
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Figure 1. Exposure protocol for wild type murine animals
The table shows the lifetime scale of the mice and the Pb exposure scenario. The red
arrowheads indicate the various time points of sacrifice and tissue collection. Control (Con)
group, Early Pb exposure group (PbE), Adult Pb exposure group (PbA) and Early and adult
Pb exposure group (Pb-EA).
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Figure 2. Total Tau expression across the lifespan and following developmental exposure to Pb
(A) Changes in the developmental profiles of tau protein expression in the cerebral cortex of
control, Early Pb exposure group (PbE), Adult Pb exposure group (PbA) and Early and adult
Pb exposure group (Pb-EA). (B) Quantification by normalization to GAPDH. (C) mRNA
levels of Tau relative to GAPDH. Each data point in the curve is the mean ± SD. *p<0.05,
**p< 0.01, ***p<0.001 compared to the control group.
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Figure 3. Protein expression of Phosphorylated Tau Thr 181 and Thr 212 across the lifespan and
following developmental exposure to Pb
(A) Changes in the developmental profiles of tau Thr 181 and 212 protein expression in the
cerebral cortex of control, Early Pb exposure group (PbE), Adult Pb exposure group (PbA)
and Early and adult Pb exposure group (Pb-EA). (B &C) Quantification by normalization to
GAPDH. Each data point in the curve is the mean ± SD. *p< 0.05 compared to the control
group.
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Figure 4. Protein expression of Phosphorylated Tau Ser 396 and Ser 235 across the lifespan and
following developmental exposure to Pb
(A) Changes in the developmental profiles of Ser 396 and 235 protein expression in the
cerebral cortex of control, Early Pb exposure group (PbE), Adult Pb exposure group (PbA)
and Early and adult Pb exposure group (Pb-EA). (B&C) Quantification by normalization to
GAPDH. Each data point in the curve is the mean ± SD. *p< 0.05 compared to the control
group.
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Figure 5. cdk5 expression across the lifespan and following developmental exposure to Pb
(A) Changes in the developmental profiles of cdk5 protein expression in the cerebral cortex
of control, Early Pb exposure group (PbE), Adult Pb exposure group (PbA) and Early and
adult Pb exposure group (Pb-EA). (B) Quantification by normalization to GAPDH. (C)
mRNA levels of CDK5 relative to GAPDH. Each data point in the curve is the mean ± SD.
*p< 0.05, ** p<0.01 compared to control group.
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Figure 6. Protein expression of p35 and p25 across the lifespan and following developmental
exposure to Pb
(A) Changes in the developmental profiles of p35 and p25 protein expression in the cerebral
cortex of control, Early Pb exposure group (PbE), Adult Pb exposure group (PbA) and Early
and Adult Pb exposure group (Pb-EA). (B) Quantification by normalization to GAPDH.
Each data point in the curve is the mean ± SD. *p< 0.05, ** p<0.01 compared to the control
group.
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Figure 7. Ser/Thr protein phosphatase levels across the lifespan and following developmental
exposure to Pb
Changes in the developmental profiles of Ser/Thr protein phosphatase levels in the cerebral
cortex of control, Early Pb exposure group (PbE), Adult Pb exposure group (PbA) and Early
and Adult Pb exposure group (Pb-EA). Each data point in the curve is the mean ± SD. *p <
0.05 compared to the control group.
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